3. Angelino, AF. Impact of psychiatric disorders on the HIV epidemic. Top HIV Med. 2008; 16(2): 99–103.
5. Chaudhury, S, Bakhla, AK, Saini, R. Prevalence, impact, and management of depression and anxiety in patients with HIV: a review. Neurobehav HIV Med. 2016; 2016(7): 15–30.
6. Forstein, M. The psychosocial impact of the acquired immune deficiency syndrome. Semin Oncol. 1984; 11(1): 77–82.
7. Silva, MC, Ximenes, RA, Miranda Filho, DB, et al. Risk-factors for non-adherence to antiretroviral therapy. Rev Inst Med Trop Sao Paulo. 2009; 51(3): 135–139.
8. Beer, L, Skarbinski, J. Adherence to antiretroviral therapy among HIV-infected adults in the United States. AIDS Educ Prev. 2014; 26(6): 521–537.
9. Farinpour, R, Miller, EN, Satz, P, et al. Psychosocial risk factors of HIV morbidity and mortality: findings from the Multicenter AIDS Cohort Study (MACS). J Clin Exp Neuropsychol. 2003; 25(5): 654–670.
10. Gonzalez, JS, Batchelder, AW, Psaros, C, et al. Depression and HIV/AIDS treatment nonadherence: a review and meta-analysis. J Acquir Immune Defic Syndr. 2011; 58(2): 181–187.
11. Leserman, J. Role of depression, stress, and trauma in HIV disease progression. Psychosom Med. 2008; 70(5): 539–545.
12. Starace, F, Ammassari, A, Trotta, MP, et al. Depression is a risk factor for suboptimal adherence to highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2002; 31(Suppl 3): S136–S139.
13. Schaecher, KL. The importance of treatment adherence in HIV. Am J Manag Care. 2013; 19(12 Suppl): S231–237.
14. Sherbourne, CD, Hays, RD, Fleishman, JA, et al. Impact of psychiatric conditions on health-related quality of life in persons with HIV infection. Am J Psychiatry. 2000; 157(2): 248–254.
15. Boillat-Blanco, N, Darling, KE, Taffe, P, et al. Impact of recommendation updates in well-controlled patients on nonrecommended antiretroviral therapies: the Swiss HIV cohort study. J Acquir Immune Defic Syndr. 2013; 62(2): 180–189.
17. Ogu, CC, Maxa, JL. Drug interactions due to cytochrome P450. Proc (Bayl Univ Med Cent). 2000; 13(4): 421–423.
18. Lund, M, Petersen, TS, Dalhoff, KP. Clinical implications of p-glycoprotein modulation in drug-drug interactions. Drugs. 2017; 77(8): 859–883.
19. Wagner, GJ, Goggin, K, Remien, RH, et al. A closer look at depression and its relationship to HIV antiretroviral adherence. Ann Behav Med. 2011; 42(3): 352–360.
20. Watkins, CC, Pieper, AA, Treisman, GJ. Safety considerations in drug treatment of depression in HIV-positive patients: an updated review. Drug Saf. 2011; 34(8): 623–639.
21. Bauer, M, Bschor, T, Pfennig, A, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders in primary care. World J Biol Psychiatry. 2007; 8(2): 67–104.
22. von Moltke, LL, Greenblatt, DJ, Giancarlo, GM, et al. Escitalopram (S-citalopram) and its metabolites in vitro: cytochromes mediating biotransformation, inhibitory effects, and comparison to R-citalopram. Drug Metab Dispos. 2001; 29(8): 1102–1109.
23. Gutierrez, MM, Rosenberg, J, Abramowitz, W. An evaluation of the potential for pharmacokinetic interaction between escitalopram and the cytochrome P450 3A4 inhibitor ritonavir. Clin Ther. 2003; 25(4): 1200–1210.
24. Gutierrez, M, Abramowitz, VE. Lack of effect of a single dose of ketoconazole on the pharmacokinetics of citalopram. Pharmacotherapy. 2001; 21(2): 163–168.
25. Malling, D, Poulsen, MN, Søgaard, B. The effect of cimetidine or omeprazole on the pharmacokinetics of escitalopram in healthy subjects. Br J Clin Pharmacol. 2005; 60(3): 287–290.
26. Celexa® (citalopram hydrobrominde) [package insert]. Irvine, CA: Allergan USA, Inc; 2016.
27. Spina, E, Pisani, F, de Leon, J. Clinically significant pharmacokinetic drug interactions of antiepileptic drugs with new antidepressants and new antipsychotics. Pharmacol Res. 2016; 106: 72–86.
28. Ouellet, D, Hsu, A, Qian, J, et al. Effect of fluoxetine on pharmacokinetics of ritonavir. Antimicrob Agents Chemother. 1998; 42(12): 3107–3112.
29. Rescriptor® (delavirdine mesylate) [package insert]. Research Triangle Park, NC: Pfizer Pharmaceuticals LLC; 2012.
30. de Maat, MM, Huitema, AD, Mulder, JW, et al. Drug interaction of fluvoxamine and fluoxetine with nevirapine in HIV-1-infected individuals. Clin Drug Investig. 2003; 23(10): 629–637.
31. DeSilva, KE, Le Flore, DB, Marston, BJ, et al. Serotonin syndrome in HIV-infected individuals receiving antiretroviral therapy and fluoxetine. AIDS. 2001; 15(10): 1281–1285.
32. Bertz, R, Foit, C, Chiu, Y-L, et al. Multiple-dose Kaletra (lopinavir/ritonavir) does not affect the pharmacokinetics of the CYP2D6 probe, desipramine (abstract 433-W). Abstract presented at: 9th Conferences on Retroviruses and Opportunistic Infections; February 24–28, 2002; Seattle, WA.
33. Grassi, B, Gambini, O, Scarone, S. Notes on the use of fluvoxamine as treatment of depression in HIV-1-infected subjects. Pharmacopsychiatry. 1995; 28(3): 93–94.
34. Jann, MW, Spratlin, V, Momary, K, et al. Lack of a pharmacokinetic drug–drug interaction with venlafaxine extended-release/indinavir and desvenlafaxine extended-release/indinavir. Eur J Clin Pharmacol. 2012; 68(5): 715–721.
35. Levin, GM, Nelson, LA, DeVane, CL, et al. A pharmacokinetic drug–drug interaction study of venlafaxine and indinavir. Psychopharmacol Bull. 2001; 35(2): 62–71.
36. Bachman, CJ, Beauleiu-Abdelahad, D, Ganey, NJ, Mullan, MJ, Levin, GM. Induction of drug efflux protein expression by venlafaxine but not desvenlafaxine. Biopharm Drug Dispos. 2011; 32(4): 233–234.
37. Skinner, MH, Kuan, HY, Pan, A, et al. Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers. Clin Pharmacol Ther. 2003; 73(3): 170–177.
38. Cymbalta® (duloxetine hydrochloride) [package insert]. Indianapolis, IN: Eli Lilly and Company; 2008.
39. Aung, GL, O’Brien, JG, Tien, PG, et al. Increased aripiprazole concentrations in an HIV-positive male concurrently taking duloxetine, darunavir, and ritonavir. Ann Pharmacother. 2010; 44(11): 1850–1854.
40. Zalma, A, von Moltke, LL, Granda, BW, et al. In vitro metabolism of trazodone by CYP3A: inhibition by ketoconazole and human immunodeficiency viral protease inhibitors. Biol Psychiatry. 2000; 47(7): 655–661.
41. Greenblatt, DJ, von Moltke, LL, Harmatz, JS, et al. Short-term exposure to low-dose ritonavir impairs clearance and enhances adverse effects of trazodone. J Clin Pharmacol. 2003; 43(4): 414–422.
42. Voican, CS, Corruble, E, Naveau, S, et al. Antidepressant-induced liver injury: a review for clinicians. Am J Psychiatry. 2014; 171(4): 404–415.
43. Elliott, AJ, Russo, J, Bergam, K, et al. Antidepressant efficacy in HIV-seropositive outpatients with major depressive disorder: an open trial of nefazodone. J Clin Psychiatry. 1999; 60(4): 226–231.
44. Elliott, AJ, Roy-Byrne, PP. Mirtazapine for depression in patients with human immunodeficiency virus. J Clin Psychopharmacol. 2000; 20(2): 265–267.
45. Wellbutrin (bupropion hydrochloride) [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2017.
46. Hogeland, GW, Swindells, S, McNabb, JC, et al. Lopinavir/ritonavir reduces bupropion plasma concentrations in healthy subjects. Clin Pharmacol Ther. 2007; 81(1): 69–75.
47. Robertson, SM, Maldarelli, F, Natarajan, V, et al. Efavirenz induces CYP2B6-mediated hydroxylation of bupropion in healthy subjects. J Acquir Immune Defic Syndr. 2008; 49(5): 513–519.
48. Kharasch, ED, Mitchell, D, Coles, R, et al. Rapid clinical induction of hepatic cytochrome P4502B6 activity by ritonavir. Antimicrob Agents Chemother. 2008; 52(5): 1663–1669.
49. Park, J, Vousden, M, Brittain, C, et al. Dose-related reduction in bupropion plasma concentrations by ritonavir. J Clin Pharmacol. 2010; 50(10): 1180–1187.
50. Currier, MB, Molina, G, Kato, M. A prospective trial of sustained-release bupropion for depression in HIV-seropositive and AIDS patients. Psychosomatics. 2003; 44(2): 120–125.
51. American Psychiatric Association (APA). Practice guidelines for the treatment of patients with major depressive disorder. 3rd ed. Am J Psychiatry. 2010; 167: 1–152.
52. Fernandez, F. Neuropsychiatric aspects of human immunodeficiency virus (HIV) infection. Curr Psychiatry Rep. 2002; 4(3): 228–231.
53. Gillman, PK. Tricyclic antidepressant pharmacology and therapeutic drug interactions updated. Br J Pharmacol. 2007; 151(6): 737–748.
54. Norvir® [package insert]. North Chicago, IL: AbbVie Inc.; June 2017.
55. Bertz, RJ, Cao, G, Cavanaugh, JH, et al. Effect of ritonavir on the pharmacokinetics of desipramine. Abstract presented at: Proceedings of the International Conference on AIDS; July 1996; Vancouver, BC.
56. Usach, I, Melis, V, Gandía, P, et al. Pharmacokinetic interaction between nevirapine and nortriptyline in rats: inhibition of nevirapine metabolism by nortriptyline. Antimicrob Agents Chemother. 2014; 58(12): 7041–7048.
57. Pieper, AA, Treisman, GJ. Drug treatment of depression in HIV-positive patients: safety considerations. Drug Saf. 2005; 28(9): 753–762.
58. Maldonado, JL, Fernandez, F, Levy, JK Acquired immunodeficiency syndrome. In: Lauterbach E, ed. Psychiatric Management of Neurologic Disease. Washington, DC: American Psychiatric Press; 2000: 271–295.
59. Linde, K, Berner, MM, Kriston, L. St John’s wort for major depression. Cochrane Database Syst Rev. 2008;(4): CD000448.
60. Knuppel, L, Linde, K. Adverse effects of St John’s wort: a systematic review. J Clin Psychiatry. 2004; 65(11): 1470–1479.
61. Izzo, AA, Ernst, E. Interactions between herbal medicines and prescribed drugs: an updated systematic review. Drugs. 2009; 69(13): 1777–1798.
62. de Maat, MM, Hoetelmans, RM, Mathôt, RA, et al. Drug interaction between St John’s wort and nevirapine. AIDS. 2001; 15(3): 420–421.
63. Piscitelli, SC, Burstein, AH, Chaitt, D, et al. Indinavir concentrations and St John’s wort. Lancet. 2000; 355(9263): 547–548.
64. Henderson, L, Yue, QY, Bergquist, C
et al. St John’s wort (Hypericum perforatum): drug interactions and clinical outcomes. Br J Clin Pharmacol. 2002; 54(4): 349–356.
65. Rosen, RC, Marin, H. Prevalence of antidepressant-associated erectile dysfunction. J Clin Psychiatry. 2003; 64(Suppl 10): 5–10.
66. Hart, TA, Mustanski, B, Ryan, DT, et al. Depression and sexual dysfunction among HIV-positive and HIV-negative men who have sex with men: mediation by use of antidepressants and recreational stimulants. Arch Sex Behav. 2015; 44(2): 399–409.
67. Elliott, AJ, Uldall, KK, Bergam, K, et al. Randomized, placebo-controlled trial of paroxetine versus imipramine in depressed HIV-positive outpatients. Am J Psychiatry. 1998; 155(3): 367–372.
68. Selzentry® (maraviroc) [package insert]. Research Triangle Park, NC: ViiV Healthcare; 2016.
69. Nittayananta, W, Chanowanna, N, Pruphetkaew, N, et al. Relationship between xerostomia and salivary flow rates in HIV-infected individuals. J Investig Clin Dent. 2013; 4(3): 164–171.
70. Younai, FS, Marcus, M, Freed, JR, et al. Self-reported oral dryness and HIV disease in a national sample of patients receiving medical care. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2001; 92(6): 629–636.
71. Badowski, M, Pandit, N. Pharmacologic management of human immunodeficiency virus wasting syndrome. Pharmacotherapy. 2014; 34(8): 858–861.
72. Koethe, JR, Jenkins, CA, Lau, B, et al. Rising obesity prevalence and weight gain among adults starting antiretroviral therapy in the United States and Canada. AIDS Res Hum Retroviruses. 2016; 32(1): 50–58.
73. Jasiak, NM, Bostwick, JR. Risk of QT/QTc prolongation among newer non-SSRI antidepressants. Ann Pharmacother. 2014; 48(12): 1620–1628.
74. Invirase® (saquinavir) [package insert]. South San Francisco, CA: Mississauga, Genentech USA, Inc.; 2016.
75. Soliman, EZ, Lundgren, JD, Roediger, MP, et al. Boosted protease inhibitors and the electrocardiographic measures of QT and PR durations. AIDS. 2011; 25(3): 367–377.
76. Anson, BD, Weaver, GR, Ackerman, MJ, et al. Blockade of HERG channels by HIV protease inhibitors. Lancet. 2005; 365(9460): 682–686.
77. Edurant [package insert]. Titusville, NJ: Janssen Therapeutics; 2011.
78. Sustiva® [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; October 2017.
79. Mollan, KR, Smurzynski, M, Eron, JJ, et al. Association between efavirenz as initial therapy for HIV-1 infection and increased risk for suicidal ideation or attempted or completed suicide: an analysis of trial data. Ann Intern Med. 2014; 161(1): 1–10.
80. Nkhoma, ET, Coumbis, J, Farr, AM, et al. No evidence of an association between efavirenz exposure and suicidality among HIV patients initiating antiretroviral therapy in a retrospective cohort study of real world data. Medicine (Baltimore). 2016; 95(3): e2480.
81. Breitbart, W, Rosenfeld, B, Kaim, M, et al. A randomized, double-blind, placebo-controlled trial of psychostimulants for the treatment of fatigue in ambulatory patients with human immunodeficiency virus disease. Arch Intern Med. 2001; 161(3): 411–420.
82. Fernandez, F, Levy, JK, Sampley, HR, et al. Effects of methylphenidate in HIV-related depression: a comparative trial with desipramine. Int J Psychiatry Med. 1995; 25(1): 53–67.
83. Wagner, GJ, Rabkin, JG, Rabkin, R. Dextroamphetamine as a treatment for depression and low energy in AIDS patients: a pilot study. J Psychosom Res. 1997; 42(4): 407–411.
84. Wagner, GJ, Rabkin, R. Effects of dextroamphetamine on depression and fatigue in men with HIV: a double-blind, placebo-controlled trial. J Clin Psychiatry. 2000; 61(6): 436–440.
85. Hinkin, CH, Castellon, SA, Hardy, DJ, Farinpour, R, Newton, T, Singer, E. Methylphenidate improves HIV-1-associated cognitive slowing. J Neuropsychiatry Clin Neurosci. 2001; 13(2): 248–254.
86. Scharko, AM. DSM psychiatric disorders in the context of pediatric HIV/AIDS. AIDS Care. 2006; 18(5): 441–445.
87. Zeegers, I, Rabie, H, Swanevelder, S, et al. Attention deficit hyperactivity and oppositional defiance disorder in HIV-infected South African children. J Trop Pediatr. 2010; 56(2): 97–102.
88. Dopheide, JA, Pliszka, SR. Attention-deficit-hyperactivity disorder: an update. Pharmacotherapy. 2009; 29(6): 656–679.
89. Koutsilieri, E, Riederer, P, du Plessis, S, et al. A short review on the relation between the dopamine transporter 10/10-repeat allele and ADHD: implications for HIV infection. Atten Defic Hyperact Disord. 2014; 6(3): 203–209.
90. Landino, J, Buckley, J, Roy, JM, et al. Guidance of pharmacotherapy in a complex psychiatric case by CYP450 DNA typing. J Am Acad Nurse Pract. 2011; 23(9): 459–463.
91. Markowitz, JS, Straughn, AB, Patrick, KS. Advances in the pharmacotherapy of attention-deficit-hyperactivity disorder: focus on methylphenidate formulations. Pharmacotherapy. 2003; 23(10): 1281–1299.
92. Domnitei, D, Madaan, V. New and extended-action treatments in the management of ADHD: a critical appraisal of lisdexamfetamine in adults and children. Neuropsychiatr Dis Treat. 2010; 6: 273–279.
93. Krishnan, S, Moncrief, S. An evaluation of the cytochrome p450 inhibition potential of lisdexamfetamine in human liver microsomes. Drug Metab Dispos. 2007; 35(1): 180–184.
94. Cortese, S, Holtmann, M, Banaschewski, T, et al. Practitioner review: current best practice in the management of adverse events during treatment with ADHD medications in children and adolescents. J Child Psychol Psychiatry. 2013; 54(3): 227–246.
95. Hennissen, L, Bakker, MJ, Banaschewski, T, et al. Cardiovascular effects of stimulant and non-stimulant medication for children and adolescents with ADHD: a systematic review and meta-analysis of trials of methylphenidate, amphetamines and atomoxetine. CNS Drugs. 2017; 31(3): 199–215.
96. Awudu, GA, Besag, FM. Cardiovascular effects of methylphenidate, amphetamines and atomoxetine in the treatment of attention-deficit hyperactivity disorder: an update. Drug Saf. 2014; 37(9): 661–676.
98. Burkholder, GA, Tamhane, AR, Salinas, JL, et al. Underutilization of aspirin for primary prevention of cardiovascular disease among HIV-infected patients. Clin Infec Dis. 2012; 55(11): 1550–1557.
99. Ribaudo, HJ, Benson, CA, Zheng, Y, et al. No risk of myocardial infarction associated with initial antiretroviral treatment containing abacavir: short and long-term results from ACTG A5001/ALLRT. Clin Infect Dis. 2011; 52(7): 929–940.
100. Elion, RA, Althoff, KN, Zhang, J, et al. Recent abacavir use increases risk of type 1 and type 2 myocardial infarctions among adults with HIV. J Acquir Immune Defic Syndr. 2018; 78(1): 62–72.
101. Chow, D, Shikuma, C, Ritchings, C, et al. Atazanavir and cardiovascular risk among human immunodeficiency virus-infected patients: a systematic review. Infect Dis Ther. 2016; 5(4): 473–489.
102. LaFleur, J, Bress, AP, Rosenblatt, L, et al. Cardiovascular outcomes among HIV-infected veterans receiving atazanavir. AIDS. 2017; 31(15): 2095–2106.
103. Wolraich, ML, Doffing, ML. Pharmacokinetic considerations in the treatment of ADHD with methylphenidate. CNS Drugs. 2004; 18(4): 243–250.
104. Helleberg, M, Pedersen, MG, Pedersen, CB, et al. Associations between HIV and schizophrenia and their effect on HIV treatment outcomes: a nationwide population-based cohort study in Denmark. Lancet HIV. 2015; 2(8): e344–350.
105. Hughes, E, Bassi, S, Gilbody, S, et al. Prevalence of HIV, hepatitis B, and hepatitis C in people with severe mental illness: a systematic review and meta-analysis. Lancet Psychiatry. 2016; 3(1): 40–48.
106. Hill, L, Lee, KC. Pharmacotherapy considerations in patients with HIV and psychiatric disorders: focus on antidepressants and antipsychotics. Ann Pharmacother. 2013; 47(1): 75–89.
107. Abilify [package insert]. Rockville, MD: Otsuka America Pharmaceutical, Inc.; 2014.
108. Tybost® [package insert]. Foster City, CA: Gilead Sciences, Inc; August 2017.
109. Hahn, M, Roll, SC. Dosing recommendations of aripiprazole depot with strong cytochrome P450 3A4 inhibitors: a relapse risk. Drug Saf Case Rep. 2016; 3(1): 5.
110. Jacobs, BS, Colbers, AP, Velthoven-Graafland, K, et al. Effect of fosamprenavir/ritonavir on the pharmacokinetics of single-dose olanzapine in healthy volunteers. Int J Antimicrob Agents. 2014; 44(2): 173–177.
111. van der Lee, MJ, Dawood, L, ter Hofstede, HJ, et al. Lopinavir/ritonavir reduces lamotrigine plasma concentrations in healthy subjects. Clin Pharmacol Ther. 2006; 80(2): 159–168.
112. Yeh, RF, Gaver, VE, Patterson, KB, et al. Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers. J Acquir Immune Defic Syndr. 2006; 42(1): 52–60.
113. Penzak, SR, Hon, YY, Lawhorn, WD, et al. Influence of ritonavir on olanzapine pharmacokinetics in healthy volunteers. J Clin Psychopharmacol. 2002; 22(4): 366–370.
114. Hantson, P, Di Fazio, V, Wallemacq, P. Toxicokinetic interaction between quetiapine and antiretroviral therapy following quetiapine overdose. Drug Metab Lett. 2010; 4(1): 7–8.
115. Pollak, PT, Zbuk, K. Quetiapine fumarate overdose: clinical and pharmacokinetic lessons from extreme conditions. Clin Pharmacol Ther. 2000; 68(1): 92–97.
116. Pollack, TM, McCoy, C, Stead, W. Clinically significant adverse events from a drug interaction between quetiapine and atazanavir-ritonavir in two patients. Pharmacotherapy. 2009; 29(11): 1386–1391.
117. Geraci, MJ, McCoy, SL, Crum, PM, et al. Antipsychotic-induced priapism in an HIV patient: a cytochrome P450-mediated drug interaction. Int J Emerg Med. 2010; 3(2): 81–84.
118. Kelly, DV, Beique, LC, Bowmer, MI. Extrapyramidal symptoms with ritonavir/indinavir plus risperidone. Ann Pharmacother. 2002; 36(5): 827–830.
119. Lee, SI, Klesmer, J, Hirsch, BE. Neuroleptic malignant syndrome associated with use of risperidone, ritonavir, and indinavir: a case report. Psychosomatics. 2000; 41(5): 453–454.
120. Jover, F, Cuadrado, JM, Andreu, L, et al. Reversible coma caused by risperidone-ritonavir interaction. Clin Neuropharmacol. 2002; 25(5): 251–253.
121. Gonzalez, LS, Kothari, K, Kasle, DA. Three cases of late onset angioedema in nursing home human immunodeficiency virus patients on ritonavir and risperidone. J Clin Psychopharmacol. 2016; 36(1): 95–97.
122. Latuda [package insert]. Marlborough, MA: Sunovion Pharmaceuticals, Inc.; 2017.
123. Reyataz® [package insert]. Princeton, NJ: Bristol-Myers Squibb; October 2017.
124. Naccarato, M, Hall, E, Wai, A, et al. A case of a probable drug interaction between lurasidone and atazanavir-based antiretroviral therapy. Antivir Ther. 2016; 21(8): 735–738.
125. Vergara-Rodriguez, P, Vibhakar, S, Watts, J. Metabolic syndrome and associated cardiovascular risk factors in the treatment of persons with human immunodeficiency virus and severe mental illness. Pharmacol Ther. 2009; 124(3): 269–278.
126. Safrin, S, Grunfeld, C. Fat distribution and metabolic changes in patients with HIV infection. AIDS. 1999; 13(18): 2493–2505.
127. Aberg, JA, Tebas, P, Overton, ET, et al. Metabolic effects of darunavir/ritonavir versus atazanavir/ritonavir in treatment-naive, HIV type 1-infected subjects over 48 weeks. AIDS Res Hum Retroviruses. 2012; 28(10): 1184–1195.
128. Molina, JM, Andrade-Villanueva, J, Echevarria, J, et al. Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study. J Acquir Immune Defic Syndr. 2010; 53(3): 323–332.
129. Ferrara, M, Umlauf, A, Sanders, C, et al. The concomitant use of second-generation antipsychotics and long-term antiretroviral therapy may be associated with increased cardiovascular risk. Psychiatry Res. 2014; 218(1–2): 201–208.
130. Nejad, SH, Gandhi, RT, Freudenreich, O. Clozapine use in HIV-infected schizophrenia patients: a case-based discussion and review. Psychosomatics. 2009; 50(6): 626–632.
131. Volberding, PA, Lagakos, SW, Koch, MA, et al. Zidovudine in asymptomatic human immunodeficiency virus infection. N Engl J Med. 1990; 322(14): 941–949.
132. Gerken, AT, McGahee, S, Keuroghlian, AS, et al. Consideration of clozapine and gender-affirming medical care for an HIV-positive person with schizophrenia and fluctuating gender identity. Harv Rev Psychiatry. 2016; 24(6): 406–415.
133. Abers, MS, Shandera, WX, Kass, JS. Neurological and psychiatric adverse effects of antiretroviral drugs. CNS Drugs. 2014; 28(2): 131–145.
134. Arendt, G, de Nocker, D, von Giesen, HJ, et al. Neuropsychiatric side effects of efavirenz therapy. Expert Opin Drug Saf. 2007; 6(2): 147–154.
135. de la Garza, CL, Paoletti-Duarte, S, Garcia-Martin, C, et al. Efavirenz-induced psychosis. AIDS. 2001; 15(14): 1911–1912.
136. Peyriere, H, Mauboussin, JM, Rouanet, I, et al. Management of sudden psychiatric disorders related to efavirenz. AIDS. 2001; 15(10): 1323–1324.
137. Wise, ME, Mistry, K, Reid, S. Drug points: neuropsychiatric complications of nevirapine treatment. BMJ. 2002; 324(7342): 879.
138. Nelson, M, Stellbrink, HJ, Podzamczer, D, et al. A comparison of neuropsychiatric adverse events during 12 weeks of treatment with etravirine and efavirenz in a treatment-naive, HIV-1-infected population. AIDS. 2011; 25(3): 335–340.
139. Miyamoto, S, Duncan, GE, Marx, CE, et al. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry. 2005; 10(1): 79–104.
140. Brogan, K, Lux, J. Management of common psychiatric conditions in the HIV-positive population. Curr HIV/AIDS Rep. 2009; 6(2): 108–115.
141. Sewell, MC, Goggin, KJ, Rabkin, JG, et al. Anxiety syndromes and symptoms among men with AIDS: a longitudinal controlled study. Psychosomatics. 2000; 41(4): 294–300.
142. Campos, LN, Guimaraes, MD, Remien, RH. Anxiety and depression symptoms as risk factors for non-adherence to antiretroviral therapy in Brazil. AIDS Behav. 2010; 14(2): 289–299.
143. Buspar [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2010.
144. Clay, PG, Adams, MM. Pseudo-parkinson disease secondary to ritonavir-buspirone interaction. Ann Pharmacother. 2003; 37(2): 202–205.
145. Ieiri, I, Tsunemitsu, S, Maeda, K, et al. Mechanisms of pharmacokinetic enhancement between ritonavir and saquinavir; micro/small dosing tests using midazolam (CYP3A4), fexofenadine (p-glycoprotein), and pravastatin (OATP1B1) as probe drugs. J Clin Pharmacol. 2013; 53(6): 654–661.
146. Schmitt, C, Hofmann, C, Riek, M, et al. Effect of saquinavir-ritonavir on cytochrome P450 3A4 activity in healthy volunteers using midazolam as a probe. Pharmacotherapy. 2009; 29(10): 1175–1181.
147. Mathias, AA, German, P, Murray, BP, et al. Pharmacokinetics and pharmacodynamics of GS-9350: a novel pharmacokinetic enhancer without anti-HIV activity. Clin Pharmacol Ther. 2010; 87(3): 322–329.
148. Kakuda, TN, Scholler-Gyure, M, Hoetelmans, RM. Pharmacokinetic interactions between etravirine and non-antiretroviral drugs. Clin Pharmacokinet. 2011; 50(1): 25–39.
149. von Moltke, LL, Greenblatt, DJ, Grassi, JM, et al. Protease inhibitors as inhibitors of human cytochromes P450: high risk associated with ritonavir. J Clin Pharmacol. 1998; 38(2): 106–111.
150. Greenblatt, DJ, von Moltke, LL, Daily, JP, et al. Extensive impairment of triazolam and alprazolam clearance by short-term low-dose ritonavir: the clinical dilemma of concurrent inhibition and induction. J Clin Psychopharmacol. 1999; 19(4): 293–296.
151. Frye, R, Bertz, R, Granneman, GR, et al. Effect of ritonavir on the pharmacokinetics and pharmacodynamics of alprazolam. Abstract presented at: Interscience Conference on Antimicrobial Agents and Chemotherapy; 1997; Toronto, Canada.
152. de Sousa Gurgel, W, da Silva Carneiro, AH, Barreto Rebouças, D, et al. Prevalence of bipolar disorder in a HIV-infected outpatient population. AIDS Care. 2013; 25(12): 1499–1503.
153. Hunt, GE, Malhi, GS, Cleary, M, et al. Comorbidity of bipolar and substance use disorders in national surveys of general populations, 1990-2015: systematic review and meta-analysis. J Affect Disord. 2016; 206: 321–330.
154. Halman, MH, Worth, JL, Sanders, KM, et al. Anticonvulsant use in the treatment of manic syndromes in patients with HIV-1 infection. J Neuropsychiatry Clin Neurosci. 1993; 5(4): 430–434.
155. Tegretol® [package insert]. East Honover, NJ: Novartis Pharmaceuticals Corporation; April 2017.
156. Bates, DE, Herman, RJ. Carbamazepine toxicity induced by lopinavir/ritonavir and nelfinavir. Ann Pharmacother. 2006; 40(6): 1190–1195.
157. Burman, W, Orr, L. Carbamazepine toxicity after starting combination antiretroviral therapy including ritonavir and efavirenz. AIDS. 2000; 14(17): 2793–2794.
158. Garcia, AB, Ibarra, AL, Etessam, JP, et al. Protease inhibitor-induced carbamazepine toxicity. Clin Neuropharmacol. 2000; 23(4): 216–218.
159. Kato, Y, Fujii, T, Mizoguchi, N, et al. Potential interaction between ritonavir and carbamazepine. Pharmacotherapy. 2000; 20(7): 851–854.
160. Mateu-de Antonio, J, Grau, S, Gimeno-Bayón, JL, et al. Ritonavir-induced carbamazepine toxicity. Ann Pharmacother. 2001; 35(1): 125–126.
161. Hugen, PW, Burger, DM, Brinkman, K, et al. Carbamazepine–indinavir interaction causes antiretroviral therapy failure. Ann Pharmacother. 2000; 34(4): 465–470.
162. Song, I, Weller, S, Patel, J, et al. Effect of carbamazepine on dolutegravir pharmacokinetics and dosing recommendation. Eur J Clin Pharmacol. 2016; 72(6): 665–670.
163. Ji, P, Damle, B, Xie, J, et al. Pharmacokinetic interaction between efavirenz and carbamazepine after multiple-dose administration in healthy subjects. J Clin Pharmacol. 2008; 48(8): 948–956.
164. Baranyai, D, Muro, E, Gödtel-Armbrust, U, et al. Reduction of nevirapine-driven HIV mutations by carbamazepine is modulated by CYP3A activity. J Antimicrob Chemother. 2014; 69(7): 1933–1937.
165. Muro, EP, Fillekes, Q, Kisanga, ER, et al. Intrapartum single-dose carbamazepine reduces nevirapine levels faster and may decrease resistance after a single dose of nevirapine for perinatal HIV prevention. J Acquir Immune Defic Syndr. 2012; 59(3): 266–273.
166. Viramune® [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; March 2017.
167. Cressey, TR, Jourdain, G, Lallemant, MJ, et al. Persistence of nevirapine exposure during the postpartum period after intrapartum single-dose nevirapine in addition to zidovudine prophylaxis for the prevention of mother-to-child transmission of HIV-1. J Acquir Immune Defic Syndr. 2005; 38(3): 283–288.
168. Guay, LA, Musoke, P, Fleming, T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet. 1999; 354(9181): 795–802.
169. Jackson, JB, Musoke, P, Fleming, T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial. Lancet. 2003; 362(9387): 859–868.
170. Muro, E, Droste, JA, Hofstede, HT, et al. Nevirapine plasma concentrations are still detectable after more than 2 weeks in the majority of women receiving single-dose nevirapine: implications for intervention studies. J Acquir Immune Defic Syndr. 2005; 39(4): 419–421.
171. Akula, SK, Rege, AB, Dreisbach, AW, et al. Valproic acid increases cerebrospinal fluid zidovudine levels in a patient with AIDS. Am J Med Sci. 1997; 313(4): 244–246.
172. Antoniou, T, Gough, K, Yoong, D. Severe anemia secondary to a probable drug interaction between zidovudine and valproic acid. Clin Infect Dis. 2004; 38(5): e38–40.
173. Lertora, JJ, Rege, AB, Greenspan, DL, et al. Pharmacokinetic interaction between zidovudine and valproic acid in patients infected with human immunodeficiency virus. Clin Pharmacol Ther. 1994; 56(3): 272–278.
174. Birbeck, GL, French, JA, Perucca, E, et al. Antiepileptic drug selection for people with HIV/AIDS: evidence-based guidelines from the ILAE and AAN. Epilepsia. 2012; 53(1): 207–214.
175. DiCenzo, R, Peterson, D, Cruttenden, K, et al. Effects of valproic acid coadministration on plasma efavirenz and lopinavir concentrations in human immunodeficiency virus-infected adults. Antimicrob Agents Chemother. 2004; 48(11): 4328–4331.
176. Saraga, M, Preisig, M, Zullino, DF. Reduced valproate plasma levels possible after introduction of efavirenz in a bipolar patient. Bipolar Disord. 2006; 8(4): 415–417.
177. Cozza, KL, Swanton, EJ, Humphreys, CW. Hepatotoxicity with combination of valproic acid, ritonavir, and nevirapine: a case report. Psychosomatics. 2000; 41(5): 452–453
178. DiCenzo, R, Peterson, DR, Cruttenden, K, et al. Effects of minocycline and valproic acid coadministration on atazanavir plasma concentrations in human immunodeficiency virus-infected adults receiving atazanavir-ritonavir. Antimicrob Agents Chemother. 2008; 52(9): 3035–3039.
179. Sheehan, NL, Brouillette, MJ, Delisle, MS, et al. Possible interaction between lopinavir/ritonavir and valproic acid exacerbates bipolar disorder. Ann Pharmacother. 2006; 40(1): 147–150.
180. Burger, DM, Huisman, A, Van Ewijk, N, et al. The effect of atazanavir and atazanavir/ritonavir on UDP-glucuronosyltransferase using lamotrigine as a phenotypic probe. Clin Pharmacol Ther. 2008; 84(6): 698–703.
181. Luther, J, Glesby, MJ. Dermatologic adverse effects of antiretroviral therapy: recognition and management. Am J Clin Dermatol. 2007; 8(4): 221–233.
182. Depakote® [package insert]. North Chicago, IL: AbbVie Inc.; October 2017.
183. Surgers, L, Lacombe, K. Hepatoxicity of new antiretrovirals: a systematic review. Clin Res Hepatol Gastroenterol. 2013; 37(2): 126–133.
184. Badalov, N, Baradarian, R, Iswara, K, et al. Drug-induced acute pancreatitis: an evidence-based review. Clin Gastroenterol Hepatol. 2007; 5(6): 648–661.
185. Mockenhaupt, M. The current understanding of Stevens-Johnson syndrome and toxic epidermal necrolysis. Expert Rev Clin Immunol. 2011; 7(6): 803–813.
186. Raymond, GS, Lori, ES, Neil, HS. Lamotrigine-induced severe cutaneous adverse reactions. Epilepsia. 1998; 39(Supp7): S22–S26.
187. Lithobid® [package insert]. Baudette, MN: Ani Pharmaceuticals, Inc.; May 2016.
188. Anastasi, JK, Capili, B. Nausea and vomiting in HIV/AIDS. Gastroenterol Nurs. 2011; 34(1): 15–24.
189. Rabeneck, L, Crane, MM, Risser, JM, et al. A simple clinical staging system that predicts progression to AIDS using CD4 count, oral thrush, and night sweats. J Gen Intern Med. 1993; 8(1): 5–9.
190. Retrovir® [package insert]. Research Triangle Park, NC: GlaxoSmithKline; May 2012.
191. Hernández, DE, Pérez, JR, Wilder, J, et al. Kaposi sarcoma associated with human immunodeficiency virus infection. Int J Dermatol. 1991; 30(2): 109–113.
192. Roberts, DE, Berman, SM, Nakasato, S, et al. Effect of lithium carbonate on zidovudine-associated neutropenia in the acquired immunodeficiency syndrome. Am J Med. 1988; 85(3): 428–431.
193. Berns, JS, Kasbekar, N. Highly active antiretroviral therapy and the kidney: an update on antiretroviral medications for nephrologists. Clin J Am Soc Nephrol. 2006; 1(1): 117–129.
194. Tivicay [package insert]. Research Triangle Park, NC: GlaxoSmithKline; November 2017.
195. Decloedt, EH, Lesosky, M, Maartens, G, et al. Renal safety of lithium in HIV-infected patients established on tenofovir disoproxil fumarate containing antiretroviral therapy: analysis from a randomized placebo-controlled trial. AIDS Res Ther. 2017; 14(1): 6.
196. Lansky, A, Brooks, JT, DiNenno, E, et al. Epidemiology of HIV in the United States. J Acquir Immune Defic Syndr. 2010; 55(Suppl 2): S64–68.
197. Arnsten, JH, Demas, PA, Grant, RW, et al. Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users. J Gen Intern Med. 2002; 17(5): 377–381.
198. Bruce, RD, Altice, FL, Moody, DE, et al. Pharmacokinetic interactions between buprenorphine/naloxone and once-daily lopinavir/ritonavir. J Acquir Immune Defic Syndr. 2010; 54(5): 511–514.
199. Methadone [package insert]. Columbus, OH: Roxane Laboratories, Inc.; April 2015.
200. Kharasch, ED, Bedynek, PS, Hoffer, C, et al. Lack of indinavir effects on methadone disposition despite inhibition of hepatic and intestinal cytochrome P4503A (CYP3A). Anesthesiology. 2012; 116(2): 432–447.
201. Kharasch, ED, Bedynek, PS, Park, S, et al. Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: I. Evidence against CYP3A mediation of methadone clearance. Clin Pharmacol Ther. 2008; 84(4): 497–505.
202. Kharasch, ED, Stubbert, K. Cytochrome P4503A does not mediate the interaction between methadone and ritonavir-lopinavir. Drug Metab Dispos. 2013; 41(12): 2166–2174.
203. Anderson, MS, Mabalot Luk, JA, Hanley, WD, et al. Effect of raltegravir on the pharmacokinetics of methadone. J Clin Pharmacol. 2010; 50(12): 1461–1466.
204. Song, I, Mark, S, Chen, S, et al. Dolutegravir does not affect methadone pharmacokinetics in opioid-dependent, HIV-seronegative subjects. Drug Alcohol Depend. 2013; 133(2): 781–784.
205. Bruce, RD, Winkle, P, Custodio, JM, et al. Investigation of the interactions between methadone and elvitegravir-cobicistat in subjects receiving chronic methadone maintenance. Antimicrob Agents Chemother. 2013; 57(12): 6154–6157.
206. Bañón, S, Moreno, A, Quereda, C, et al. A clinical and pharmacokinetic study of the combination of etravirine plus raltegravir in HIV patients with expanded intolerance or resistance. J Int AIDS Soc. 2014; 17(4 Suppl 3): 19804.
207. Geletko, SM, Erickson, AD. Decreased methadone effect after ritonavir initiation. Pharmacotherapy. 2000; 20(1): 93–94.
208. Gerber, JG, Rosenkranz, S, Segal, Y, et al. Effect of ritonavir/saquinavir on stereoselective pharmacokinetics of methadone: results of AIDS Clinical Trials Group (ACTG) 401. J Acquir Immune Defic Syndr. 2001; 27(2): 153–160.
209. Jamois, C, Smith, P, Morrison, R, et al. Effect of saquinavir/ritonavir (1000/100 mg bid) on the pharmacokinetics of methadone in opiate-dependent HIV-negative patients on stable methadone maintenance therapy. Addict Biol. 2009; 14(3): 321–327.
210. Shelton, MJ, Cloen, D, DiFrancesco, R, et al. The effects of once-daily saquinavir/minidose ritonavir on the pharmacokinetics of methadone. J Clin Pharmacol. 2004; 44(3): 293–304.
211. López-Cortés, LF, Viciana, P, Ruiz-Valderas, R, et al. Efficacy, safety and pharmacokinetic of once-daily boosted saquinavir (1500/100 mg) together with 2 nucleos(t)ide reverse transcriptase inhibitors in real life: a multicentre prospective study. AIDS Res Ther. 2010; 7: 5.
212. Sekar, V, Tomaka, F, Lefebvre, E, et al. Pharmacokinetic interactions between darunavir/ritonavir and opioid maintenance therapy using methadone or buprenorphine/naloxone. J Clin Pharmacol. 2011; 51(2): 271–278.
213. Cao, YJ, Smith, PF, Wire, MB, et al. Pharmacokinetics and pharmacodynamics of methadone enantiomers after coadministration with fosamprenavir-ritonavir in opioid-dependent subjects. Pharmacotherapy. 2008; 28(7): 863–874.
214. Kharasch, ED, Hoffer, C, Whittington, D, et al. Methadone pharmacokinetics are independent of cytochrome P4503A (CYP3A) activity and gastrointestinal drug transport: insights from methadone interactions with ritonavir/indinavir. Anesthesiology. 2009; 110(3): 660–672.
215. Clarke, S, Mulcahy, F, Bergin, C, et al. Absence of opioid withdrawal symptoms in patients receiving methadone and the protease inhibitor lopinavir-ritonavir. Clin Infect Dis. 2002; 34(8): 1143–1145.
216. Stevens, RC, Rapaport, S, Maroldo-Connelly, L, et al. Lack of methadone dose alterations or withdrawal symptoms during therapy with lopinavir/ritonavir. J Acquir Immune Defic Syndr. 2003; 33(5): 650–651.
217. McCance-Katz, EF, Rainey, PM, Friedland, G, et al. The protease inhibitor lopinavir-ritonavir may produce opiate withdrawal in methadone-maintained patients. Clin Infect Dis. 2003; 37(4): 476–482.
218. Lüthi, B, Huttner, A, Speck, RF, et al. Methadone-induced torsade de pointes after stopping lopinavir-ritonavir. Eur J Clin Microbiol Infect Dis. 2007; 26(5): 367–369.
219. Hsyu, PH, Lillibridge, J, Daniels, E, et al. Pharmacokinetic interaction of nelfinavir and methadone in intravenous drug users. Biopharm Drug Dispos. 2006; 27(2): 61–68.
220. Kharasch, ED, Walker, A, Whittington, D, et al. Methadone metabolism and clearance are induced by nelfinavir despite inhibition of cytochrome P4503A (CYP3A) activity. Drug Alcohol Depend. 2009; 101(3): 158–168.
221. McCance-Katz, EF, Rainey, PM, Smith, P, et al. Drug interactions between opioids and antiretroviral medications: interaction between methadone, LAAM, and nelfinavir. Am J Addict. 2004; 13(2): 163–180.
222. McCance-Katz, EF, Farber, S, Selwyn, PA, et al. Decrease in methadone levels with nelfinavir mesylate. Am J Psychiatry. 2000; 157(3): 481.
223. Friedland, G, Andrews, L, Schreibman, T, et al. Lack of an effect of atazanavir on steady-state pharmacokinetics of methadone in patients chronically treated for opiate addiction. AIDS. 2005; 19(15): 1635–1641.
224. Haberl, A, Moesch, M, Nisius, G, et al. Atazanavir plasma concentrations are impaired in HIV-1-infected adults simultaneously taking a methadone oral solution in a once-daily observed therapy setting. Eur J Clin Pharmacol. 2010; 66(4): 375–381.
225. Higgins, N, Zingman, BS, Slish, J, et al. Factors associated with altered pharmacokinetics in substance users and non-substance users receiving lopinavir and atazanavir. Am J Addict. 2007; 16(6): 488–494.
226. Altice, FL, Friedland, GH, Cooney, EL. Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone. AIDS. 1999; 13(8): 957–962.
227. Arroyo, E, Valenzuela, B, Portilla, J, et al. Pharmacokinetics of methadone in human-immunodeficiency-virus-infected patients receiving nevirapine once daily. Eur J Clin Pharmacol. 2007; 63(7): 669–675.
228. Boffito, M, Rossati, A, Reynolds, HE, et al. Undefined duration of opiate withdrawal induced by efavirenz in drug users with HIV infection and undergoing chronic methadone treatment. AIDS Res Hum Retroviruses. 2002; 18(5): 341–342.
229. Clarke, SM, Mulcahy, FM, Tjia, J, et al. Pharmacokinetic interactions of nevirapine and methadone and guidelines for use of nevirapine to treat injection drug users. Clin Infect Dis. 2001; 33(9): 1595–1597.
230. Clarke, SM, Mulcahy, FM, Tjia, J, et al. The pharmacokinetics of methadone in HIV-positive patients receiving the non-nucleoside reverse transcriptase inhibitor efavirenz. Br J Clin Pharmacol. 2001; 51(3): 213–217.
231. Esteban, J, Pellín Mde, L, Gimeno, C, et al. Increase of R-/S-methadone enantiomer concentration ratio in serum of patients treated with either nevirapine or efavirenz. Drug Metab Lett. 2008; 2(4): 269–279.
232. Heelon, MW, Meade, LB. Methadone withdrawal when starting an antiretroviral regimen including nevirapine. Pharmacotherapy. 1999; 19(4): 471–472.
233. Manfredi, R, Calza, L, Chiodo, F. Prospective, open-label comparative study of liver toxicity in an unselected population of HIV-infected patients treated for the first time with efavirenz or nevirapine. HIV Clin Trials. 2005; 6(6): 302–311.
234. Marzolini, C, Troillet, N, Telenti, A, et al. Efavirenz decreases methadone blood concentrations. AIDS. 2000; 14(9): 1291–1292.
235. Otero, MJ, Fuertes, A, Sánchez, R, et al. Nevirapine-induced withdrawal symptoms in HIV patients on methadone maintenance programme: an alert. AIDS. 1999; 13(8): 1004–1005.
236. Pelet, A, Favrat, B, Cavassini, M, et al. Usefulness of methadone plasma concentration measurement in patients receiving nevirapine or efavirenz. Am J Drug Alcohol Abuse. 2011; 37(4): 264–268.
237. Pinzani, V, Faucherre, V, Peyriere, H, et al. Methadone withdrawal symptoms with nevirapine and efavirenz. Ann Pharmacother. 2000; 34(3): 405–407.
238. Staszewski, S, Haberl, A, Gute, P, et al. Nevirapine/didanosine/lamivudine once daily in HIV-1-infected intravenous drug users. Antivir Ther. 1998; 3(Suppl 4): 55–56.
239. Stocker, H, Kruse, G, Kreckel, P, et al. Nevirapine significantly reduces the levels of racemic methadone and (R)-methadone in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother. 2004; 48(11): 4148–4153.
240. Schöller-Gyüre, M, van den Brink, W, Kakuda, TN, et al. Pharmacokinetic and pharmacodynamic study of the concomitant administration of methadone and TMC125 in HIV-negative volunteers. J Clin Pharmacol. 2008; 48(3): 322–329.
241. Crauwels, HM, van Heeswijk, RP, Vandevoorde, A, et al. The effect of rilpivirine on the pharmacokinetics of methadone in HIV-negative volunteers. J Clin Pharmacol. 2014; 54(2): 133–140.
242. Rainey, PM, Friedland, GH, Snidow, JW, et al. The pharmacokinetics of methadone following co-administration with a lamivudine/zidovudine combination tablet in opiate-dependent subjects. Am J Addict. 2002; 11(1): 66–74.
243. Smith, PF, Kearney, BP, Liaw, S, et al. Effect of tenofovir disoproxil fumarate on the pharmacokinetics and pharmacodynamics of total, R-, and S-methadone. Pharmacotherapy. 2004; 24(8): 970–977.
244. Rainey, PM, Friedland, G, McCance-Katz, EF, et al. Interaction of methadone with didanosine and stavudine. J Acquir Immune Defic Syndr. 2000; 24(3): 241–248.
245. Burger, DM, Meenhorst, PL, ten Napel, CH, et al. Pharmacokinetic variability of zidovudine in HIV-infected individuals: subgroup analysis and drug interactions. AIDS. 1994; 8(12): 1683–1689.
246. McCance-Katz, EF, Rainey, PM, Jatlow, P, Friedland, G. Methadone effects on zidovudine disposition (AIDS Clinical Trials Group 262). J Acquir Immune Defic Syndr Hum Retrovirol. 1998; 18(5): 435–443.
247. Schwartz, EL, Brechbühl, AB, Kahl, P, et al. Pharmacokinetic interactions of zidovudine and methadone in intravenous drug-using patients with HIV infection. J Acquir Immune Defic Syndr. 1992; 5(6): 619–626.
248. Buprenorphine [package insert]. Columbus, OH: Roxane Laboratories, Inc.; February 2015.
249. Bruce, RD, Altice, FL, Moody, DE, et al. Pharmacokinetic interactions between buprenorphine/naloxone and tipranavir/ritonavir in HIV-negative subjects chronically receiving buprenorphine/naloxone. Drug Alcohol Depend. 2009; 105(3): 234–239.
250. Bruce, RD, Moody, DE, Fang, WB, et al. Tipranavir/ritonavir induction of buprenorphine glucuronide metabolism in HIV-negative subjects chronically receiving buprenorphine/naloxone. Am J Drug Alcohol Abuse. 2011; 37(4): 224–228.
251. McCance-Katz, EF, Moody, DE, Morse, GD, et al. Interaction between buprenorphine and atazanavir or atazanavir/ritonavir. Drug Alcohol Depend. 2007; 91(2–3): 269–278.
252. McCance-Katz, EF, Moody, DE, Smith, PF, et al. Interactions between buprenorphine and antiretrovirals. II. The protease inhibitors nelfinavir, lopinavir/ritonavir, and ritonavir. Clin Infect Dis. 2006; 43(Suppl 4): S235–246.
253. Gruber, VA, Rainey, PM, Moody, DE. Interactions between buprenorphine and the protease inhibitors darunavir-ritonavir and fosamprenavir-ritonavir. Clin Infect Dis. 2012; 54(3): 414–423.
254. Berson, A, Fau, D, Fornacciari, R, et al. Mechanisms for experimental buprenorphine hepatotoxicity: major role of mitochondrial dysfunction versus metabolic activation. J Hepatol. 2001; 34(2): 261–269.
255. Peyrière, H, Tatem, L, Bories, C, Pageaux, GP, Blayac, JP, Larrey, D. Hepatitis after intravenous injection of sublingual buprenorphine in acute hepatitis C carriers: report of two cases of disappearance of viral replication after acute hepatitis. Ann Pharmacother. 2009; 43(5): 973–977.
256. Vergara-Rodriguez, P, Tozzi, MJ, Botsko, M, et al. Hepatic safety and lack of antiretroviral interactions with buprenorphine/naloxone in HIV-infected opioid-dependent patients. J Acquir Immune Defic Syndr. 2011; 56(Suppl 1): S62–67.
257. Maremmani, I, Pacini, M, Cesaroni, C, et al. QTc interval prolongation in patients on long-term methadone maintenance therapy. Eur Addict Res. 2005; 11(1): 44–49.
258. Chinello, P, Lisena, FP, Angeletti, C, et al. Role of antiretroviral treatment in prolonging QTc interval in HIV-positive patients. J Infect. 2007; 54(6): 597–602.
259. Gallagher, DP, Kieran, J, Sheehan, G, et al. Ritonavir-boosted atazanavir, methadone, and ventricular tachycardia: 2 case reports. Clin Infect Dis. 2008; 47(3): e36–38.
260. Baker, JR, Best, AM, Pade, PA, et al. Effect of buprenorphine and antiretroviral agents on the QT interval in opioid-dependent patients. Ann Pharmacother. 2006; 40(3): 392–396.
261. Prosser, JM, Mills, A, Rhim, ES, et al. Torsade de pointes caused by polypharmacy and substance abuse in a patient with human immunodeficiency virus. Int J Emerg Med. 2008; 1(3): 217–220.
262. Rocco, A, Compare, D, Angrisani, D, et al. Alcoholic disease: liver and beyond. World J Gastroenterol. 2014; 20(40): 14652–14659.
263. Abrescia, N, D’Abbraccio, M, Figoni, M, et al. Hepatotoxicity of antiretroviral drugs. Curr Pharm Des. 2005; 11(28): 3697–3710.
264. Harris, J, Pillinger, M, Fromstein, D, et al. Risk factors for medication non-adherence in an HIV infected population in the Dominican Republic. AIDS Behav. 2011; 15(7): 1410–1415.
265. Antabuse® [package insert]. Bensalem, PA: Rising Pharmaceuticals, Inc.; August 2016.
266. Campral® [package insert]. St. Louis, MO: Forest Pharmaceuticals, Inc.; January 2012.
267. ReVia® [package insert]. Horsham, PA: Teva Pharmaceutical Industries; October 2013.
268. Vivitrol® [package insert]. Waltham, MA: Alkermes, Inc.; December 2015.
269. McCance-Katz, EF, Gruber, VA, Beatty, G, et al. Interaction of disulfiram with antiretroviral medications: efavirenz increases while atazanavir decreases disulfiram effect on enzymes of alcohol metabolism. Am J Addict. 2014; 23(2): 137–144.
270. McCance-Katz, EF, Rainey, PM, Friedland, G, et al. Effect of opioid dependence pharmacotherapies on zidovudine disposition. Am J Addict. 2001; 10(4): 296–307.
271. Cvetkovic, RS, Goa, KL. Lopinavir/ritonavir: a review of its use in the management of HIV infection. Drugs. 2003; 63(8): 769–802.
272. Kaletra® [package insert]. North Chicago, IL: AbbVie Inc.; 2017.
273. Núñez, M, Soriano, V. Hepatotoxicity of antiretrovirals: incidence, mechanisms and management. Drug Saf. 2005; 28(1): 53–66.
274. Koubar, SH, Estrella, MM, Warrier, R, et al. Rhabdomyolysis in an HIV cohort: epidemiology, causes and outcomes. BMC Nephrol. 2017; 18(1): 242.